In bio news is Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow Biosciences, which is on a hunt to find potential partners for research collaboration on stem cells in China.
Last month, RBCC made bio news with the announcement, that it was in talks to acquire a license to use a NASA-developed bioreactor to multiply adult stem cells for research. As RBCC closes in on an agreement with the cutting-edge device’s license holders, Amarantus BioSciences (OTCBB: AMBS), China has emerged as a logical location to set up shop conducting medical research using the powerful tool.
With a massive, growing population of senior citizens and a scientific community that is receptive to advanced stem cell research, China could be an ideal choice for RBCC’s work. Seniors are at the highest risk for devastating neurological disorders such as Parkinson’s and Alzheimer’s, and the country’s number of senior citizens will hit 437 million by 2051.
“Right now, all signs point to China as the obvious choice for both our company and our shareholders,” said RBCC CEO Patrick Brown. “The cheaper labor costs there, as well as a receptive market, make China a logical location to search for potential research partners that can utilize the bioassembler technology in a meaningful way.
“There is certainly no space-age technology like the bioassembler available in China today,” he added.
RBCC plans to pursue a license to use the bioreactor for stem cell expansion in China and other markets around the world potentially in excess of $100 billion.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
For further deal information visit Current Agreements (subscription required)
Read: more on dealtalk deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity